Fresenius Medical Care AG FMS

Fresenius Medical Care AG & Co. KGaA es una empresa de diálisis renal. La empresa proporciona cuidados de diálisis y servicios relacionados a personas que sufren de enfermedad renal en etapa terminal (ESRD), así como otros servicios de salud. Los segmentos de la empresa incluyen el Segmento de América del Norte, el Segmento de Europa, Oriente Medio y África (EMEA), el Segmento de Asia-Pacífico y el Segmento de América Latina. La empresa desarrolla y fabrica una variedad de máquinas de diálisis, sistemas y productos desechables. Hasta el 31 de diciembre de 2016, la empresa vendió sus productos a clientes en más de 120 países y también los utilizó en sus operaciones internas de servicios de salud. Los servicios de Coordinación de Cuidados de la empresa incluyen la entrega coordinada de servicios de farmacia, servicios especializados vasculares, cardiovasculares y endovasculares, servicios de pruebas de laboratorio no relacionadas con diálisis, servicios médicos, servicios de hospitalistas e intensivistas, servicios de planes de salud, servicios de centros de cirugía ambulatoria y servicios de atención de urgencia.

Con 45 acciones de FMS (USD 1.009,13) habrías recibido USD 38,70 en dividendos en los últimos 12 meses.

FMS hizo una división de acciones (split) de 2:1 el 4 de diciembre de 2012: cada acción se convirtió en 2. Cambió la cantidad de acciones y su precio, pero no el valor total de la inversión.

• Zacks Investment Research 3 sept

  Can Fresenius Medical's 5008X Rollout Drive the Next Growth Phase?

  Fresenius Medical Care is scaling up its 5008X CAREsystem rollout, converting 227 U.S. clinics to the new technology by July 2026, representing 10% of its machine base. The company has performed over 600,000 treatments including 100,000+ high-volume hemodiafiltration treatments, showing clinical promise with 40% fewer muscle cramps. However, near-term headwinds include weak U.S. treatment volume growth (-0.9%), TDAPA reimbursement pressure (€50 million drag expected), and significant rollout implementation costs.

  

• Zacks Investment Research 3 sept

  Reasons to Retain Fresenius Medical Stock in Your Portfolio for Now

  Fresenius Medical Care (FMS) is improving profitability through its FME25+ transformation program and expanding high-volume HDF and 5008X dialysis systems. However, the company faces significant challenges including persistent U.S. treatment volume weakness, TDAPA reimbursement reversals expected to create a €50 million headwind in 2026, China regulatory pressure, and inflation-related cost risks. The company maintains a Zacks Rank #3 (Hold) with consensus 2026 earnings expected to decline 7% year-over-year.

  

• GlobeNewswire Inc. 29 jul

  New Cross-Study Analysis from Spherix Global Insights Combines Physician, Dietitian and Patient Chart Data to Show Access Barriers Still Curbing Xphozah Uptake Ahead of the TDAPA Cliff

  A new analysis by Spherix Global Insights reveals that access barriers, not efficacy issues, are limiting Xphozah (tenapanor) uptake in the dialysis hyperphosphatemia market. Nephrologists report they would nearly triple Xphozah use without reimbursement and coverage obstacles. However, the drug faces persistence challenges with gastrointestinal tolerability causing discontinuation rates to double to 8%. The findings also show physicians significantly overestimate phosphorus control and combination therapy use among patients. As the TDAPA reimbursement program expires at the end of 2026, phosphate-lowering therapies will face a flattened competitive landscape.

  

• GlobeNewswire Inc. 20 jul

  Urology Devices Market Size to Reach USD 80.0 Billion by 2035 | SNS Insider

  The global urology devices market is valued at USD 39.23 billion in 2025 and is projected to reach USD 80.0 billion by 2035, growing at a CAGR of 7.35%. Growth is driven by rising demand for robotic-assisted surgery, kidney disease treatment, and minimally invasive procedures. North America leads the market while Asia Pacific records the fastest growth.